Disease-specific subanalyses showed a trend toward an association between PIK3CA and KRAS mutations in colorectal cancer (17/24 [71%] vs. 21/44 [48%]; p=0.08) and associations between PIK3CA mutations and KRAS mutations (6/17 [35%] vs. 2/28 [7%], p=0.04) and MAPK mutations (8/13 [62%] vs. 2/15 [13%], p=0.02) in ovarian and endometrial cancers combined. This evidence concerns the gene PIK3CA and endometrial cancer.